Corvus Corporate Presentation November 2025 ITK Inhibitor Platform Opportunity Novel MOA with broad opportunities in oncology and immune diseases The Power to Control Immunity Forward-Looking Statements / Safe Harbor This presentation and the accompanying oral presentation contain "forward‐looking" statements related to the potential of the Company's product candidates including soquelitinib and the interim results from the Phase 1 trial of soquelitinib in patients with atopic dermatitis, the design and tim ...